Medication
Victoza is daily liraglutide approved for Type 2 diabetes — the same molecule as Saxenda at lower max dose. Generic liraglutide entered the U.S. market in 2024.
| Generic name | liraglutide |
| Brand manufacturer | Novo Nordisk |
| FDA indication | Type 2 diabetes |
| FDA approval year | 2010 |
| Form | Subcutaneous injection (prefilled pen) |
| Schedule | Daily |
| List price (cash) | $938/month |
For drug-class comparisons, see our medication-comparison hub:
Coverage varies significantly by carrier and employer plan. See our insurance hub for plan-specific guidance:
Victoza is the brand name for liraglutide, manufactured by Novo Nordisk. Victoza is daily liraglutide approved for Type 2 diabetes — the same molecule as Saxenda at lower max dose. Generic liraglutide entered the U.S. market in 2024.
Victoza list price is approximately $938/month. Insurance may cover it with prior authorization for FDA-approved indications.
FDA-approved 2010. Indication: Type 2 diabetes.
Doses available: 0.6 mg, 1.2 mg, 1.8 mg. Schedule: Daily. Always follow your prescribing clinician's titration plan.
See our medication comparisons hub for head-to-head pages on Wegovy vs Zepbound, Ozempic vs Wegovy, and semaglutide vs tirzepatide.
Note: This page is an editorial overview, not medical advice. Always consult a licensed clinician about whether Victoza is appropriate for you.